CHICAGO TRUST Co NA Grows Position in Edwards Lifesciences Corporation $EW

Key Points

• CHICAGO TRUST Co NA increased its position in Edwards Lifesciences Corporation by 111.9% during the 2nd quarter, holding 11,663 shares valued at approximately $912,000.
• Several analysts have upgraded their ratings on Edwards Lifesciences, with Royal Bank Of Canada raising its price target from $85.00 to $89.00, and BTIG Research increasing it to $100.00.
• Edwards Lifesciences reported a strong quarterly performance with earnings per share of $0.67, exceeding expectations and demonstrating an 11.9% year-over-year revenue growth to $1.53 billion.

CHICAGO TRUST Co NA raised its holdings in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 111.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,663 shares of the medical research company's stock after acquiring an additional 6,158 shares during the period. CHICAGO TRUST Co NA's holdings in Edwards Lifesciences were worth $912,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the 1st quarter valued at about $26,000. SouthState Corp bought a new position in shares of Edwards Lifesciences during the 1st quarter valued at about $27,000. Global X Japan Co. Ltd. increased its position in shares of Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock valued at $29,000 after purchasing an additional 216 shares during the last quarter. Tradewinds Capital Management LLC increased its position in shares of Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock valued at $29,000 after purchasing an additional 205 shares during the last quarter. Finally, Rossby Financial LCC bought a new position in shares of Edwards Lifesciences during the 1st quarter valued at about $29,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Ratings Changes

EW has been the topic of several recent research reports. Royal Bank Of Canada increased their price objective on Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Truist Financial increased their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research report on Friday, July 25th. Daiwa America upgraded Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Stifel Nicolaus set a $85.00 price target on Edwards Lifesciences and gave the stock a "buy" rating in a research report on Monday. Finally, BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 price target on the stock in a research report on Tuesday, July 29th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $86.61.

Edwards Lifesciences Trading Up 1.2%

NYSE EW opened at $74.61 on Wednesday. Edwards Lifesciences Corporation has a fifty-two week low of $64.00 and a fifty-two week high of $83.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a 50 day simple moving average of $78.55 and a two-hundred day simple moving average of $75.58. The stock has a market cap of $43.80 billion, a P/E ratio of 10.73, a price-to-earnings-growth ratio of 3.55 and a beta of 1.07.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion during the quarter, compared to analysts' expectations of $1.49 billion. During the same quarter last year, the business posted $0.70 EPS. The business's revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider owned 206,900 shares of the company's stock, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.